SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001610618-23-000102
Filing Date
2023-11-16
Accepted
2023-11-16 16:05:12
Documents
12
Period of Report
2023-11-09
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CIDARA THERAPEUTICS, INC. FORM 8-K cdtx-20231109.htm   iXBRL 8-K 26695
  Complete submission text file 0001610618-23-000102.txt   155817

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdtx-20231109.xsd EX-101.SCH 1899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdtx-20231109_lab.xml EX-101.LAB 25156
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdtx-20231109_pre.xml EX-101.PRE 13048
6 EXTRACTED XBRL INSTANCE DOCUMENT cdtx-20231109_htm.xml XML 2829
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 231414593
SIC: 2836 Biological Products, (No Diagnostic Substances)